Trial Profile
Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Edivoxetine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Pharmacogenomic; Registrational
- 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Dec 2012 Planned End Date changed from 1 Jan 2013 to 1 Dec 2012 as reported by ClinicalTrials.gov record.